198 related articles for article (PubMed ID: 7507539)
41. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
42. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors.
White CM
Pharmacotherapy; 1998; 18(3):588-99. PubMed ID: 9620109
[TBL] [Abstract][Full Text] [Related]
43. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
Burnier M; Brunner HR
Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
[TBL] [Abstract][Full Text] [Related]
44. Critical assessment of ACE inhibitors. Part 2.
Howes LG
Aust Fam Physician; 1995 Apr; 24(4):639, 641-3. PubMed ID: 7771972
[TBL] [Abstract][Full Text] [Related]
45. Angiotensin II exerts positive feedback on the intrarenal renin-angiotensin system by an angiotensin converting enzyme-dependent mechanism.
Sadjadi J; Kramer GL; Yu CH; Welborn MB; Modrall JG
J Surg Res; 2005 Dec; 129(2):272-7. PubMed ID: 15992826
[TBL] [Abstract][Full Text] [Related]
46. Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases.
Magen E; Viskoper RJ
Isr Med Assoc J; 2000 Dec; 2(12):929-34. PubMed ID: 11344778
[TBL] [Abstract][Full Text] [Related]
47. Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design.
Douglas RG; Ehlers MR; Sturrock ED
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):535-41. PubMed ID: 23351021
[TBL] [Abstract][Full Text] [Related]
48. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
Dzau VJ; Bernstein K; Celermajer D; Cohen J; Dahlöf B; Deanfield J; Diez J; Drexler H; Ferrari R; Van Gilst W; Hansson L; Hornig B; Husain A; Johnston C; Lazar H; Lonn E; Lüscher T; Mancini J; Mimran A; Pepine C; Rabelink T; Remme W; Ruilope L; Ruzicka M; Schunkert H; Swedberg K; Unger T; Vaughan D; Weber M
Cardiovasc Drugs Ther; 2002 Mar; 16(2):149-60. PubMed ID: 12090908
[TBL] [Abstract][Full Text] [Related]
49. [Prospective trends in the study of the therapeutic action of angiotensin-converting enzyme inhibitors in cardiovascular diseases].
Novikova LS; Arabidze GG
Ter Arkh; 1990; 62(1):118-23. PubMed ID: 2159193
[No Abstract] [Full Text] [Related]
50. Overview of the angiotensin-converting-enzyme inhibitors.
Piepho RW
Am J Health Syst Pharm; 2000 Oct; 57 Suppl 1():S3-7. PubMed ID: 11030016
[TBL] [Abstract][Full Text] [Related]
51. Tissue angiotensin converting enzyme inhibition. Relevant to clinical practice?
Lees KR; MacFadyen RJ; Reid JL
Am J Hypertens; 1990 Nov; 3(11):266S-272S. PubMed ID: 2175623
[TBL] [Abstract][Full Text] [Related]
52. Tissue ACE inhibition and organ protection.
Dal Palù C
Clin Physiol Biochem; 1992; 9(3):87-8. PubMed ID: 1302162
[No Abstract] [Full Text] [Related]
53. Inhibitory activities of baicalin against renin and angiotensin-converting enzyme.
Deng YF; Aluko RE; Jin Q; Zhang Y; Yuan LJ
Pharm Biol; 2012 Apr; 50(4):401-6. PubMed ID: 22136493
[TBL] [Abstract][Full Text] [Related]
54. [ACE inhibitor: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
Kuwabara Y; Komuro I
Nihon Rinsho; 2007 May; 65 Suppl 5():66-73. PubMed ID: 17571367
[No Abstract] [Full Text] [Related]
55. [Angiotensin converting enzyme domain structure and properties].
Kugaevskaia EV
Biomed Khim; 2005; 51(6):567-80. PubMed ID: 16521820
[TBL] [Abstract][Full Text] [Related]
56. Angiotensin-converting enzyme activity in postmortem human tissues.
Lieberman J; Sastre A
Lab Invest; 1983 Jun; 48(6):711-7. PubMed ID: 6304422
[TBL] [Abstract][Full Text] [Related]
57. Pharmacological differentiation of angiotensin-converting enzyme inhibitors.
Kostis JB
J Hum Hypertens; 1989 Jun; 3 Suppl 1():119-25. PubMed ID: 2674437
[TBL] [Abstract][Full Text] [Related]
58. Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.
Dzau VJ
Drugs; 1990; 39 Suppl 2():11-6. PubMed ID: 2160882
[TBL] [Abstract][Full Text] [Related]
59. Angiotensin-converting enzyme in renal and cerebral tissue and implications for successful blood pressure management.
Reams GP
Am J Cardiol; 1992 Apr; 69(10):59C-64C. PubMed ID: 1312296
[TBL] [Abstract][Full Text] [Related]
60. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives.
Kaur P; Muthuraman A; Kaur M
ACS Chem Neurosci; 2015 Apr; 6(4):508-21. PubMed ID: 25680080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
